Page 34 - Clinical Development News Today

Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript February 26, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-1.14 EPS, expectations were $-0.86. Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]

- Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial - Petosemtamab in 2L+ HNSCC phase 3 trial planned to initiate mid-2024; interim clinical data planned for 2H24 - Petosemtamab in 2L CRC: cohort planned to initiate in 2024 - Zeno in NRG1+ cancer: Sufficient clinical data expected in 1H24 to support potential BLA submissions - Based on the Company’s current operating plan, existing cash, cash ...

Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that it will be presenting at the upcoming B. Riley Securities' Radiopharma Investor...

Patients with HIV who have suppressed viral loads and pre-existing resistance will be able to use bictegravir with this FDA approval.

Biogen Inc. has announced a significant advancement in the treatment of amyotrophic lateral sclerosis (ALS), commonly known as motor neuron disease (MND).

Last week (February 22), it was announced a recent survey conducted jointly by Climedo and Siteworks has shed light on the perspectives of more than 65 primarily European-based study physicians.

As the landscape of healthcare continues to evolve, so too does the field of drug delivery.

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Feb 27, 2024--

2023 Total revenues of $199M; +99% vs. 20224Q 2023 Total revenues of $58M; +62% vs. 20224Q 2023 Net income of $1M; Non-GAAP net income of $7M$302M of cash and cash equivalents and investments at...

Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate VYVGART® was launched in September 2023 in China and we...